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Cytomegalovirus (CMV) has been linked with vascular pathology and is a common infectious 
complication of renal transplantation. We addressed the relative importance of transplantation per 
se and CMV seropositivity as determinants of vascular pathology.   
 
Findings: 
Levels of CMV antibody increased with age and were higher in renal transplant recipients than 
healthy controls (p<0.001). The optimal general linear model predicting vascular endothelial 
function through flow mediated-dilation of the brachial artery  (FMD; R2=0.31, p<0.0001) 
included CMV seropositivity as a marginal effect (p=0.068), with age (p=0.013, <55 years), 
gender (p<0.0001) and transplantation (p<0.0001). The same procedure identified no influence of 
CMV antibodies on maximum thickness of the carotid arterial wall, with the optimal model 
(R2=0.30, p<0.001) being based entirely on age (p<0.0001).  
 
Conclusions:  
The presence of CMV antibody was associated weakly with the endothelial dysfunction  
independent of age and transplantation. Validation of this association with other measures of CMV 
burden is clinically important because periodic CMV prophylaxis of selected patients stable on 







Most people carry cytomegalovirus (CMV) as a lifelong latent infection, with periodic 
reactivations triggered by inflammation or stress. CMV is also a common infectious complication 
of renal transplantation (1). Before prophylaxis was available, one in three renal transplant 
recipients (RTR) experienced pathologies associated with CMV. For example; 12 of 141 RTR in 
one study, died with disseminated CMV infection (2). In Australia, it is common practice to 
administer valganciclovir as prophylaxis for 12-26 weeks after transplantation, based on donor and 
recipient CMV seropositivity and clinical risk. Under a similar regimen, CMV replication was 
detected in 33% of previously seropositive RTR and 21% of those who were seronegative at 
transplantation (3). However the long-term use of valganciclovir after this initial prophylactic 
period is not standard as there are uncertain benefits and cost. However CMV reactivations are 
implicated in deterioration in renal function (4), new onset type II diabetes (5) and vascular 
pathologies. Cardiovascular disease after renal transplantation is a common long-term 
complication of successful renal transplantation and is more frequent in CMV-positive patients 
(6,7). Periodic CMV prophylaxis of selected patients stable on anti-rejection therapy is feasible 
and has the potential to reduce these adverse outcomes. 
  
Several studies associate the presence of CMV-DNA in tissues removed during surgery for 
abdominal aortic aneurysm with expression of inflammatory mediators (8, 9). Higher CMV 
antibody titres are linked with increased blood pressure in young men (10) and coronary artery 
disease requiring surgery (11). Here we assess whether levels of CMV antibodies or a simple 
dichotomy of seropositive versus negative independently predict large vessel health assessed by 
carotid intima media thickness (cIMT) and flow mediated dilatation (FMD) of the brachial artery. 
cIMT is an independent predictor of clinical cardiovascular events, including myocardial 
infarction and stroke (12). Brachial arterial FMD is assessed by high-resolution ultrasound after 
blood flow is occluded for a few minutes. The measurement reflects endothelium-dependent 
vasodilator function. It is validated as a surrogate of endothelial function of the coronary 








Patients and controls 
Renal transplant recipients (RTR; n=82) were recruited from the renal clinics at Royal Perth 
Hospital (RPH), Western Australia. Inclusion criteria were clinically stable >2 years after 
transplantation, no CMV disease or reactivation within 6 months of blood collection and no anti-
viral treatment. Age-matched healthy controls (n=81) were recruited through local advertisements. 
Demographic details are provided in Table 1. Written informed consent was obtained from each 
participant. The project was approved by the Human Ethics Committees of Royal Perth Hospital, 
University of Western Australia and Curtin University. 
 
CMV DNA and antibody 
CMV-reactive IgG was quantitated using a lysate of human foreskin fibroblasts (HFF) infected 
with strain AD169. Cells were harvested after 7 days, sonicated and stored at -800C. Uninfected 
HFF were prepared as a negative control. Parallel microtitre plates were coated at 0.5µg/ml 
(overnight, 40C) with CMV lysate, HFF lysate, CMV gB (glycoprotein B) prepared in hamster 
ovary cells (Chiron Diagnostics; Medfield, MA) and CMV IE-1 (Immediate early 1) prepared in 
E.coli (Miltenyi Biotech; Cologne, Germany). Plates were then blocked with 5%BSA in PBS and 
washed. Plasma samples pre-diluted in 2%BSA in PBS were run alongside standard plasma from a 
CMV-seropositive healthy donor and assigned a value of 1000 arbitrary units (AU/ml) for each 
antigen. Plates were washed after 2hrs and horse-radish peroxide conjugated anti-human IgG 
(Sigma-Aldrich; St Louis, MI) diluted 1:4000 in 2%BSA in PBS was added for 1hr. 
Tetramethylbenzidine substrate (Sigma-Aldrich) was added, colour development was stopped with 
1M H2SO4 and plates were read at 450nm. CMV seronegativity was defined using the CMV lysate 
assay as <3 standard deviations above the mean antibody levels recorded in 11 samples that were 
seronegative by the ARCHITECT CMV IgG assay (Abbott Diagnostic Systems; Lake Forrest, IL), 
creating a cut-off of 3623AU/ml. As a few individuals meeting this criterion had antibodies 
detectable with gB or IE-1, analyses were repeated using cut-offs of 340AU/ml gB and 
3500AU/ml IE-1 antibody. 
 
Clinical assessments 
To assess cIMT, the common carotid arteries were examined in accordance with guidelines from 
the American Society of Echocardiography (14).  Briefly; the anterolateral, posterolateral and 
mediolateral planes were acquired using a 12-15 MHz multi-frequency linear array probe attached 
to a high resolution ultrasound machine (Aspen, Acuson; Mountain View, CA). Subjects lay 
supine with a slight hyperextension of the neck and a 45° lateral flexion away from the side 
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scanned.  The vessel was scanned to exclude any carotid plaque. An R-wave triggered optimal 
recording of the far wall, 1cm proximal to the carotid bulb, was directly encoded and stored as a 
digital DICOM file for post hoc analysis.  
 
After a 10 to 20-minute rest period, brachial artery diameter response to FMD was assessed using 
a 12-15 MHz multi-frequency linear array probe attached to a high resolution ultrasound machine, 
(15).  Briefly, subjects lay supine with their arms extended at ~80° from their torso. A rapid 
inflation/deflation pneumatic cuff was placed around the arm distal to the olecranon process. 
When an optimal B-mode image was obtained, images were collected using a fixed insonation 
angle (<60°). Baseline images were recorded for 1 min, before the forearm cuff was inflated to 
220mm Hg for 5mins. Recording resumed 30sec prior to cuff deflation, and continued for 5mins 
post-deflation. FMD is presented as the relative (%) rise from the baseline diameter.  
 
Diameters were analysed with custom-designed edge-detection and wall-tracking software to 
minimise investigator bias.  Briefly; a region of interest is drawn around the B-mode image of the 
vessel segment, and the edges are detected automatically.  Over 200 individual measurements are 
taken from each frame.  For cIMT analysis, the median value is calculated to represent a single 
“composite cIMT”.  Three sets of these composite values from common carotid arteries are used to 
determine the mean lumen diameter and cIMT.  Analyses of the reproducibility gave a CV of 6.7-
10.5% for FMD (16) and 3.5% for cIMT (17). 
 
Statistical analysis 
Statistical analyses were performed using Prism 5 (GraphPad Software, La Jolla, CA) and SAS 
(Version 9.2, 2008; Cary, NC). Univariate comparisons used non-parametric Mann–Whitney tests 
and Spearman’s correlations. Multivariate associations between independent variables 
(transplantation, age and gender) and measures of CMV antibody (lysate, gB, IE-1) as dependent 
variables were sought with a separate general linear model (GLM) for each outcome.  GLM were 
then developed with %FMD or maximum cIMT as the outcome, to assess the influence of 
transplantation, gender, age (in quartiles), BMI (in tertiles), systolic and diastolic blood pressures 
(in quartiles) and CMV antibodies (in quartiles). Categories were created to assess whether the 
relationship with %FMD approximated linearity.  They were amalgamated where there appeared 
to be a ‘step function’ rather than a linear relationship, or removed if the relationship appeared to 
be linear.  In each case, backward elimination was used to obtain the most parsimonious model.  A 
p-value<0.05 was taken to indicate a statistically significant association, but p<0.10 was noted.  
	 6	
RESULTS AND DISCUSSION 
 
The 82 RTR cases and 81 healthy controls were similar in age and gender (Table 1).  RTR had 
significantly higher levels of antibody reactive with CMV (lysate, p<0.0001; gB, p<0.0001; and 
IE-1, p=0.009) than controls. This remained true when the analysis was restricted to CMV 
seropositive individuals (Table 1). The optimal GLM for CMV lysate (R2=0.19, p<0.001) included 
age (p=0.006) and transplantation (p<0.0001) as significantly associated variables. Similar results 
were obtained with gB antibody (R2=0.16, p<0.0001 with age at p=0.027 and transplantation at 
p<0.0001), but the optimal model for IE-1 antibody (R2=0.12, p<0.001) included transplantation 
(p=0.007), gender (p=0.004) and age (p=0.025). In univariate analyses, gender affected levels of 
IE-1 antibodies (Wilcoxon rank sum, p=0.013).  
 
When RTR and controls were considered together, levels of CMV-reactive antibodies were 
inversely related to the %FMD [lysate r=-0.27, p=0.0008; gB r=-0.29, p=0.0003; IE-1 r=-0.22, 
p=0.0065] suggesting an association with impaired vascular function.  While these negative 
associations persisted amongst RTR and control participants analysed separately, the correlations 
were not significantly different from zero (data not shown).  This reflected the reduced range of 
CMV antibody and %FMD levels, and smaller sample sizes. Accordingly amongst individuals 
who were CMV-seropositive, univariate analyses (Wilcoxon tests) showed that RTR had impaired 
vascular function when assessed by the diameter of the brachial artery or %FMD (Table 1). CMV 
seropositivity decreased the %FMD in RTR compared with CMV negative RTR (p=0.066), but 
this effect was not detected in controls.  
 
The optimal GLM (R2=0.317, p<0.0001) included the presence of CMV lysate antibody 
(p=0.068), age >55 years (p=0.013), gender (p<0.0001) and transplantation (p<0.0001). The 
outcome was similar using CMV gB antibody (R2=0.317, p<0.0001 with p=0.065 for gB) but there 
was no link with CMV IE-1 antibody (R2=0.317, p<0.0001 with p=0.381 for IE-1). In all models 
tested, BMI and blood pressure (systolic or diastolic) showed no significant association with FMD.   
 
Measures of cIMT did not differ between RTR or controls irrespective of CMV status. There was 
no relationship between the presence of CMV antibodies and maximum cIMT values, with the 
optimal GLM (R2=0.29, p<0.001) being based entirely on age (p<0.0001, linear term: mean cIMT 
increased by 0.074 per decade of life). Plaques were detected in only 11 cases, so Fisher’s Exact 
tests were used to assess associations with the independent variables.  These analyses associated 
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the presence of plaques with transplantation (Fishers test; p=0.003), but found no link with CMV 
lysate antibody (p=0.64), IE-1 antibody (p=0.72) or gB antibody (p=0.56). 
 
Overall there was a weak association between CMV seropositivity and the earliest marker of 
vascular dysfunction (%FMD), but not with cIMT, blood pressure or the presence of plaques. The 
negative findings may reflect the use of antibodies to mark the burden of CMV disease, the small 
sample size and/or the assessment of individuals with minimal or no symptoms of CMV 
replication or cardiovascular disease. The absence of CMV replication may be critical as there are 
additional mechanisms by which active CMV replication may cause vasculopathy – this includes 
the induction of arginase II or endothelin receptor type B (18,19). Alternatively TLR2 mediates 
interactions between CMV and platelets that lead to pro-angiogenic responses (20) and there may 
be direct effects of proteins encoded by CMV, such as HCMV UL7 - a homologue of the 
CEACAM1 pro-angiogenic factor (21).   
 
CMV antibody levels must be interpreted in the context of a lifetime of chronic exposure. In HIV 
patients, a higher CMV antibody level may mark a better immune response and consequently 
lower CMV replication (22). Alternatively, higher CMV antibody titres may suggest repeated 
reactivations of CMV antigens in individuals with subtle immune deficiencies and chronic 
immune activation, explaining the high titres seen in patients with advanced HIV disease or 
chronic obstructive pulmonary disease (23). It is also possible that these conditions (like renal 
transplantation) potentiate reactivations of CMV. Here CMV antibody levels rose with age and 
with transplantation, both of which affected FMD so the role of CMV is difficult to discern. We 
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CMV +  
Controls  
CMV-  A vs B A vs C C vs D 
A B C D P e P  P 
n 69 13 51 30   
 Male:Female 39:30 7:6 21:30 17:13 1.00f 0.14 0.25 
Age (years) 57(31-76)d 53(33-62) 55(21-86) 49(31-73) 0.14 0.15 0.47 

















CMV gBa 32(2.5-293) 0.007(0-0.3) 11(0.2-40) 0.1(0-2) <0.0001 <0.0001 <0.0001 
CMV IE-1a 12(0.5-477) 3(1.5-9.2) 9.2 (0.9-156) 4.2(1.5-51) <0.0001 0.055 0.003 
 















ba inflated (mm)  4.2(2.8-5.9) 4.7(3.2-5.4) 3.7(2.4-5.4) 3.9(2.9-5.8) 0.42 0.001 0.54 
%FMDc  3.5(0-16) 5.9(2.3-13) 7.9(1.4-14) 7.8(1.5-18) 0.066 <0.0001 0.43 

















Right cIMT 0.63(0.43-1.3) 0.68(0.57-1) 0.65(0.42-1.2) 0.58(0.46-0.89) 0.25 0.96 0.21 
Plaques (yes:no) 6:56 4:8 1:50 0:30 0.25f 0.13 1.00 
 















BP - diastolic 72(58-96) 71(60-84) 71(52-91) 71(57-98) 0.93 0.38 0.99 
	
a	antibody	assessed	in	AU/ml	divided	by	1000	
b	diameter	of	brachial	artery	(ba)	
c	[(ba	inflated-ba	at	rest)/ba	at	rest]	x	100	
d	median	(range)	for	all	continuous	variables	
e	Mann	Whitney	Rank	Sum	test	unless	otherwise	specified	
f	Fisher’s	Exact	test	
	
